FDA Places Partial Clinical Hold on Bright Minds’ BMB-101 Epilepsy Trial
+1 new source since this summary was written
The U.S. Food and Drug Administration placed Bright Minds Biosciences’ planned U.S. Phase 2 BMB-101 study for developmental and epileptic encephalopathies on partial clinical hold. The agency cited toxicity observed in mice and inadequate pharmacokinetic and juvenile-toxicity data for enrolling pediatric patients. Bright Minds said the restriction is confined to the U.S. study, while its shares were reported down 52.67% to $25.02.
Why it matters
The hold prevents the proposed U.S. study from proceeding as planned and may require more data or studies before it can advance. The FDA’s detailed letter is still pending, and Bright Minds has given no timetable for resolving the restriction.
Key facts
- 1The FDA placed Bright Minds’ investigational new drug application and BMB-101-105 protocol under a partial clinical hold. rttnews.com
- 2The FDA identified mouse toxicity and insufficient pharmacokinetic and juvenile-toxicity evidence to support pediatric enrollment. finance.yahoo.com
- 3The FDA told Bright Minds it would provide the formal hold letter within 30 days. finance.yahoo.com
- 4Bright Minds said the restriction applies to the planned U.S. study and leaves its other clinical programs outside the hold. finance.yahoo.com
- 5Bright Minds shares were reported at $25.02, down 52.67%. rttnews.com
- 6Jefferies cut its price target to $110 from $145 while retaining a Buy rating. investing.com
Open questions
- The FDA’s full explanation and recommendations have not yet been released.
- Bright Minds has not established when the hold might be lifted or whether the U.S. study will proceed.
- Jefferies expects the relevant Phase II trial initiations in 2027 rather than the fourth quarter of 2026, but this timing is an analyst forecast rather than company-confirmed guidance.
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.